Innovative and effective method for the treatment of metastatic prostate cancer
WHAT IS THERAPY WITH PREPARATION OF LUTETIUM 177-PSMA (177LU-PSMA)?
Therapy with a radioactive drug Lutetium 177-PSMA is an effective treatment for metastatic prostate cancer. This treatment is used, if other methods are ineffective or poorly tolerated by the patient. The main goal of therapy is to reduce the sizes of the tumor, slowing down the growth of metastases, relieving the patient from pain and other symptoms of the disease. Experts say: the patient feels much better in a relatively short time after the beginning of the treatment. This is confirmed by clinical trials, as therapy shows good efficacy and a high percentage of remissions. Only few medical centers in the world offeres such an innovative treatment method.
HOW DOES THE THERAPY WITH PREPARATION OF LUTETIUM 177-PSMA WORK?
There is a protein on the surface of prostate cells, it is called a prostate-specific membrane antigen (PSMA). In case of prostate cancer, the amount of PSMA is greatly increased. If prostate cancer has spread (metastasized) to other areas of the body, PSMA will also be detected there. The drug Lutetium 177-PSMA is connecting with the PSMA receptors on cancer cells, according to the “key-lock” principle, thus the delivered radioactive isotope Lutetium 177 destroys the cancer cells.
HOW IS THE THERAPY WITH PREPARATION OF LUTETIUM 177-PSMA IMPLEMENTED?
- Treatment sessions with Lutetium 177-PSMA are conducted on an outpatient basis.
- Before administering PET CT treatment with 18F-PSMA or 68Ga-PSMA to determine, if there is an increased expression of a prostate-specific membrane antigen. In 5-10% of cases, the disease does not cause overexpression of PSMA, which means that this therapy is not suitable for the patient.
- The drug is administered intravenously, and PET-CT is performed before leaving the clinic to assess the distribution of the drug in the body.
- The treatment on average consists of 2-6 cycles with an interval of 6-8 weeks.
ONE DAY BEFORE THE TREATMENT
(for this therapy is recommended stay at the clinic is for 5 – 10 days)
Arrival at the clinic
Consultation of oncologist
Full blood test
THE PROCEDURE OF THE THERAPY WITH PREPARATION OF LUTETIUM 177-PSMA
Therapy of Lutetium 177-PSMA, followed by examination of PSMA PET-CT.
When you leave the clinic, you will be provided with the necessary information.
SIDE EFFECTS OF THE THERAPY
Most patients, who receive Lutetium 177-PSMA therapy, do not face serious side effects.
Dryness in mouth and/or eyes (up to 30% of cases)
Nausea and vomiting (up to 10% of cases).
Suppression of normal blood formation in metastatic bone lesions.
PATIENT ROAD MAP
APPOINTMENT FOR THE TREATMENT
Request for treatment by phone or in an electronic form with your medical information: your epicrisis (report from health care facilities), general clinical and biochemical blood test (performed in the last 10 days), PSMA study with PET-CT, with confirmed accumulations of PSMA in tumor tissues made in the last 2 months.
Based on these documents, doctor makes an assessment of the health on the basis of the information you have provided and makes the decision on the possibility of the therapy application.
You will be sent a proposal for treatment, which includes a contract and an invoice in electronic form for prepayment.
Payment of the invoice must be made no later than 2 weeks before the agreed date of treatment.